CC-98633 is a BCMA targeted Chimeric Antigen Receptor (CAR) T Cell therapy that is being evaluated in multiple myeloma.

SparkCures ID 381
Developed By Juno Therapeutics, a Subsidiary of Celgene
Generic Name CC-98633
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)


There are no resources, links or videos to display for this treatment.